Massachusetts COVID-19 Vaccine Bulletin - Week of 9/14/2023
All individuals aged 6 months and older are advised to receive the 2023–2024 COVID-19 vaccine, which contains the XBB component, to safeguard against severe COVID-19 during the upcoming fall and winter.
Bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the U.S. New Pfizer and Moderna vaccines, targeting current variants, are available.
ACIP and CDC recommend the 2023–2024 COVID-19 vaccine for individuals ≥6 months of age.
An updated Novavax vaccine is not yet available. Authorizations or approvals for 2023 – 2024 Novavax COVID-19 vaccine will be determined by FDA (anticipated soon) with CDC recommendations to follow shortly thereafter.